NCT07013916View on ClinicalTrials.gov

Fructose is a Metabolic and Inflammatory Pathogenic Factor in Metabolic Dysfunction-associated Steatohepatitis (MASH)

NARecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2026

Conditions
MASH - Metabolic Dysfunction-Associated SteatohepatitisMASH With FibrosisSteatosis of Liver
Interventions
DIETARY_SUPPLEMENT

fructose

Fructose powder

DIETARY_SUPPLEMENT

glucose

Glucose powder

Trial Locations (2)

E1 1FR

RECRUITING

Royal London Hospital, London

E1 2AT

RECRUITING

Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London

All Listed Sponsors
collaborator

King's College London

OTHER

collaborator

University of Surrey

OTHER

lead

Queen Mary University of London

OTHER

NCT07013916 - Fructose is a Metabolic and Inflammatory Pathogenic Factor in Metabolic Dysfunction-associated Steatohepatitis (MASH) | Biotech Hunter | Biotech Hunter